Gabazinebromide | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H18BrN3O3 |
| Molar mass | 368.231 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Gabazine (SR-95531) is adrug that acts as anantagonist atGABAAreceptors. It is used in scientific research and has no role in medicine, as it would be expected to produceconvulsions if used in humans.[1]
Gabazine binds to the GABA recognition site of the receptor-channel complex and acts as anallosteric inhibitor of channel opening.[2] The net effect is to reduce GABA-mediatedsynaptic inhibition by inhibitingchloride flux across the cell membrane, and thus inhibiting neuronal hyperpolarization. While phasic (synaptic) inhibition is gabazine-sensitive, tonic (extrasynaptic) inhibition is relatively gabazine-insensitive.[3]
Gabazine has been found to bind to and antagonize α4βδsubunit-containing GABAA receptors, which may represent theGHB receptor.[4]
Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |